Nocturnal Enuresis Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2026-2036

Market Overview:

The nocturnal enuresis market reached a value of USD 1.5 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2025. Looking forward, IMARC Group expects the top 7 major markets to reach USD 2.4 Billion by 2036, exhibiting a growth rate (CAGR) of 4.50% during 2026-2036.

The nocturnal enuresis market has been comprehensively analyzed in IMARC's new report titled "Nocturnal Enuresis Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2026-2036". Nocturnal enuresis, commonly known as bedwetting, is a condition characterized by the involuntary release of urine during sleep. It is a relatively common issue that can affect individuals of various ages, from young children to adults. The primary symptom of nocturnal enuresis is waking up to find wet sheets or clothing due to the inability to control urination during the night. It can occur occasionally or persistently, and individuals suffering from the ailment may experience feelings of embarrassment, shame, or distress as a result. Additionally, nocturnal enuresis can have social and psychological impacts, thereby affecting self-esteem and interpersonal relationships. Diagnosing the condition typically involves a comprehensive evaluation by a healthcare professional, such as a pediatrician or urologist. The diagnostic process often begins with a detailed medical history review and physical examination to rule out any underlying medical disorders or contributing factors. The healthcare professional may inquire about the frequency and pattern of bedwetting episodes, family history, and other relevant symptoms. Various additional procedures, including urine analysis to check for signs of infection and bladder function tests to assess bladder capacity and urine flow, may be conducted. In some cases, urodynamic testing is also utilized to evaluate the structure and function of the urinary system.

The growing cases of deficiency or insufficient release of the antidiuretic hormone during sleep, which can result in increased urine production, thereby leading to bedwetting episodes, are primarily driving the nocturnal enuresis market. Apart from this, the rising incidences of various associated risk factors, including delayed bladder maturity, genetic predisposition, small bladder capacity, deep sleep patterns, urinary tract infections, constipation, sleep disorders, etc., are also bolstering the market growth. Furthermore, the widespread adoption of several effective drugs, such as tofenacin, desmopressin, imipramine, etc., to reduce bladder muscle contractions and increase bladder capacity is creating a positive outlook for the market. Besides this, the escalating utilization of cognitive-behavioral therapy (CBT) techniques, including habit reversal training and relaxation exercises, for addressing anxiety, stress, and low self-esteem associated with the ailment is also augmenting the market growth. Additionally, the emerging popularity of neurostimulation therapies, such as sacral nerve stimulation, which involve the use of implanted devices that deliver electrical impulses to specific nerves or areas involved in bladder control, is expected to drive the nocturnal enuresis market in the coming years. 

IMARC Group's new report provides an exhaustive analysis of the nocturnal enuresis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for nocturnal enuresis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the nocturnal enuresis market in any manner.

Time Period of the Study

• Base Year: 2025
• Historical Period: 2020-2025
• Market Forecast: 2026-2036
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the nocturnal enuresis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the nocturnal enuresis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current nocturnal enuresis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the nocturnal enuresis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2025 and how are they expected to perform till 2036?
• What was the country-wise size of the nocturnal enuresis across the seven major markets in 2025 and what will it look like in 2036?
• What is the growth rate of the nocturnal enuresis across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2020-2036) of nocturnal enuresis across the seven major markets?
• What is the number of prevalent cases (2020-2036) of nocturnal enuresis by age across the seven major markets?
• What is the number of prevalent cases (2020-2036) of nocturnal enuresis by gender across the seven major markets?
• What is the number of prevalent cases (2020-2036) of nocturnal enuresis by type across the seven major markets?
• How many patients are diagnosed (2020-2036) with nocturnal enuresis across the seven major markets?
• What is the size of the nocturnal enuresis patient pool (2020-2025) across the seven major markets?
• What would be the forecasted patient pool (2026-2036) across the seven major markets?
• What are the key factors driving the epidemiological trend nocturnal enuresis of?
• What will be the growth rate of patients across the seven major markets?

Nocturnal Enuresis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for nocturnal enuresis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the nocturnal enuresis market?
• What are the key regulatory events related to the nocturnal enuresis market?
• What is the structure of clinical trial landscape by status related to the nocturnal enuresis market?
• What is the structure of clinical trial landscape by phase related to the nocturnal enuresis market?
• What is the structure of clinical trial landscape by route of administration related to the nocturnal enuresis market?